Efficacy and safety of a 4% hydroquinone cream (Melanoderm 4%) for the treatment of melasma: a randomized controlled split-face study.

Mesoestetic Pharma group S.L.0 个研究点开始时间: 2013年11月12日最近更新: 2014年3月10日

适应症

试验速览

暂无简介。

•Adult women aged between 18-75 years old.
•Fitzpatrick phototypes I to IV.
•Presenting noderate to severe facial melasma facial, with a basal MASI Index between 10 and 20.
•Women of childbearing potential must use an adecuate contraceptive method to avoid pregnancy and must have a negative pregnancy test in a maximum of 72 hours before receiving the trial treatment.
•Breastfeeding women will not be included in the study.
•Having given freely and expressly her informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 20
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 20

•Those with any history of allergy or hypersensitivity to a cosmetic product, hydroquinone, or one of the ingredients of the investigational products.
•Fitzpatrick phototype V.
•Skin pigmentation diseases different to melasma.
•Evidence of active cancer disease or diagnosis of cancer in the last year.
•Those receiving any topical or oral treatment that could interfere with melasma.
•Pregnant or breastfeeding women, or those expecting to get pregnant during the study.
•Evidence or suspicion of low compliance with the study visits and proecedures.
•Participation in other clinical trial simultaneously or in the previous 3 months.

发起方

Mesoestetic Pharma group S.L.